Endocrinol Metab.  2025 Apr;40(2):236-246. 10.3803/EnM.2024.2136.

Study Protocol of Expanded Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro-EXP)

• Moon JH
• Lee EK
• Cha W
• Chai YJ
• Cho SW
• Choi JY
• Choi SY
• Chu AJ
• Chung EJ
• Hwangbo Y
• Jeong WJ
• Jung YS
• Kim K
• Kim MJ
• Kim Sj
• Kim W
• Kim YH
• Lee CY
• Lee JY
• Lee KE
• Lee YK
• Lim H
• Park DJ
• Park SK
• Ryu CH
• Ryu J
• Seok J
• Song YS
• Yi KH
• Yu HW
• White E
• Mastrocostas K
• Clifton-Bligh RJ
• Glover A
• Gild ML
• Kim Jh
• Park YJ

• KMID: 2567178
• DOI: http://doi.org/10.3803/EnM.2024.2136

Abstract

Background
Active surveillance (AS) has emerged as a viable management strategy for low-risk papillary thyroid microcarcinoma (PTMC), following pioneering trials at Kuma Hospital and the Cancer Institute Hospital in Japan. Numerous prospective cohort studies have since validated AS as a management option for low-risk PTMC, leading to its inclusion in thyroid cancer guidelines across various countries. From 2016 to 2020, the Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) enrolled 1,177 patients, providing comprehensive data on PTMC progression, sonographic predictors of progression, quality of life, surgical outcomes, and cost-effectiveness when comparing AS to immediate surgery. The second phase of MAeSTro (MAeSTro-EXP) expands AS to low-risk papillary thyroid carcinoma (PTC) tumors larger than 1 cm, driven by the hypothesis that overall risk assessment outweighs absolute tumor size in surgical decision-making.
Methods
This protocol aims to address whether limiting AS to tumors smaller than 1 cm may result in unnecessary surgeries for low-risk PTCs detected during their rapid initial growth phase. By expanding the AS criteria to include tumors up to 1.5 cm, while simultaneously refining and standardizing the criteria for risk assessment and disease progression, we aim to minimize overtreatment and maintain rigorous monitoring to improve patient outcomes.
Conclusion
This study will contribute to optimizing AS guidelines and enhance our understanding of the natural course and appropriate management of low-risk PTCs. Additionally, MAeSTro-EXP involves a multinational collaboration between South Korea and Australia. This cross-country study aims to identify cultural and racial differences in the management of low-risk PTC, thereby enriching the global understanding of AS practices and their applicability across diverse populations.

Keyword

Thyroid cancer, papillary; Watchful waiting; Immediate surgery; Study protocol

Figure

• 

Reference

1. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003; 13:381–7.

2. Sugitani I, Toda K, Yamada K, Yamamoto N, Ikenaga M, Fujimoto Y. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg. 2010; 34:1222–31.

3. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014; 24:27–34.

4. Nagaoka R, Ebina A, Toda K, Jikuzono T, Saitou M, Sen M, et al. Multifocality and progression of papillary thyroid microcarcinoma during active surveillance. World J Surg. 2021; 45:2769–76.

5. Rosario PW, Mourao GF, Calsolari MR. Active surveillance in adults with low-risk papillary thyroid microcarcinomas: a prospective study. Horm Metab Res. 2019; 51:703–8.

6. Lee EK, Moon JH, Hwangbo Y, Ryu CH, Cho SW, Choi JY, et al. Progression of low-risk papillary thyroid microcarcinoma during active surveillance: interim analysis of a multicenter prospective cohort study of active surveillance on papillary thyroid microcarcinoma in Korea. Thyroid. 2022; 32:1328–36.

7. Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg. 2017; 143:1015–20.

8. Molinaro E, Campopiano MC, Pieruzzi L, Matrone A, Agate L, Bottici V, et al. Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at a single Italian center. J Clin Endocrinol Metab. 2020; 105:e172–80.

9. Sanabria A. Experience with active surveillance of thyroid low-risk carcinoma in a developing country. Thyroid. 2020; 30:985–91.

10. Sugitani I, Ito Y, Takeuchi D, Nakayama H, Masaki C, Shindo H, et al. Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: consensus statements from the Japan Association of Endocrine Surgery Task Force on management for papillary thyroid microcarcinoma. Thyroid. 2021; 31:183–92.

11. Horiguchi K, Yoshida Y, Iwaku K, Emoto N, Kasahara T, Sato J, et al. Position paper from the Japan Thyroid Association task force on the management of low-risk papillary thyroid microcarcinoma (T1aN0M0) in adults. Endocr J. 2021; 68:763–80.

12. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26:1–133.

13. Jarzab B, Dedecjus M, Lewinski A, Adamczewski Z, Bakula-Zalewska E, Baldys-Waligorska A, et al. Diagnosis and treatment of thyroid cancer in adult patients: recommendations of Polish Scientific Societies and the National Oncological Strategy: 2022 update. Endokrynol Pol. 2022; 73:173–300.

14. Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30:1856–83.

15. Cho YY, Lee CR, Kang HC, Koo BS, Kwon H, Kim SW, et al. Korean Thyroid Association guidelines on the management of differentiated thyroid cancers: Part I. Initial management of differentiated thyroid cancers. Chapter 2. Surgical management of thyroid cancer 2024. Int J Thyroidol. 2024; 17:30–52.

16. Moon JH, Kim JH, Lee EK, Lee KE, Kong SH, Kim YK, et al. Study protocol of multicenter prospective cohort study of active surveillance on papillary thyroid microcarcinoma (MAeSTro). Endocrinol Metab (Seoul). 2018; 33:278–86.

17. Kong SH, Ryu J, Kim MJ, Cho SW, Song YS, Yi KH, et al. Longitudinal assessment of quality of life according to treatment options in low-risk papillary thyroid microcarcinoma patients: active surveillance or immediate surgery (interim analysis of MAeSTro). Thyroid. 2019; 29:1089–96.

18. Moon JH, Ryu CH, Cho SW, Choi JY, Chung EJ, Hah JH, et al. Effect of initial treatment choice on 2-year quality of life in patients with low-risk papillary thyroid microcarcinoma. J Clin Endocrinol Metab. 2021; 106:724–35.

19. Hwangbo Y, Choi JY, Lee EK, Ryu CH, Cho SW, Chung EJ, et al. A cross-sectional survey of patient treatment choice in a multicenter prospective cohort study on active surveillance of papillary thyroid microcarcinoma (MAeSTro). Thyroid. 2022; 32:772–80.

20. Kim K, Choi JY, Kim SJ, Lee EK, Lee YK, Ryu JS, et al. Active surveillance versus immediate surgery for low-risk papillary thyroid microcarcinoma patients in South Korea: a cost-minimization analysis from the MAeSTro Study. Thyroid. 2022; 32:648–56.

21. Hwang H, Choi JY, Yu HW, Moon JH, Kim JH, Lee EK, et al. Surgical outcomes in patients with low-risk papillary thyroid microcarcinoma from MAeSTro Study: immediate operation versus delayed operation after active surveillance: a multicenter prospective cohort study. Ann Surg. 2023; 278:e1087–95.

22. Lee JY, Kim JH, Kim YK, Lee CY, Lee EK, Moon JH, et al. US predictors of papillary thyroid microcarcinoma progression at active surveillance. Radiology. 2023; 309:e230006.

23. Anderson KL Jr, Youngwirth LM, Scheri RP, Stang MT, Roman SA, Sosa JA. T1a versus T1b differentiated thyroid cancers: do we need to make the distinction? Thyroid. 2016; 26:1046–52.

24. Wang LY, Nixon IJ, Palmer FL, Thomas D, Tuttle RM, Shaha AR, et al. Comparable outcomes for patients with pT1a and pT1b differentiated thyroid cancer: is there a need for change in the AJCC classification system? Surgery. 2014; 156:1484–90.

25. Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014; 260:601–7.

26. Ito Y, Masuoka H, Fukushima M, Inoue H, Kihara M, Tomoda C, et al. Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy. World J Surg. 2010; 34:1285–90.

27. Wang TS, Goffredo P, Sosa JA, Roman SA. Papillary thyroid microcarcinoma: an over-treated malignancy? World J Surg. 2014; 38:2297–303.

28. Rossi R, Roti E, Trasforini G, Pansini G, Cavazzini L, Zatelli MC, et al. Differentiated thyroid cancers 11-20 mm in diameter have clinical and histopathologic characteristics suggesting higher aggressiveness than those < or =10 mm. Thyroid. 2008; 18:309–15.

29. Ho AS, Kim S, Zalt C, Melany ML, Chen IE, Vasquez J, et al. Expanded parameters in active surveillance for low-risk papillary thyroid carcinoma: a nonrandomized controlled trial. JAMA Oncol. 2022; 8:1588–96.

30. Sakai T, Sugitani I, Ebina A, Fukuoka O, Toda K, Mitani H, et al. Active surveillance for T1bN0M0 papillary thyroid carcinoma. Thyroid. 2019; 29:59–63.

31. Sawka AM, Ghai S, Tomlinson G, Rotstein L, Gilbert R, Gullane P, et al. A protocol for a Canadian prospective observational study of decision-making on active surveillance or surgery for low-risk papillary thyroid cancer. BMJ Open. 2018; 8:e020298.

32. Sawka AM, Ghai S, Tomlinson G, Baxter NN, Corsten M, Imran SA, et al. A protocol for a pan-Canadian prospective observational study on active surveillance or surgery for very low risk papillary thyroid cancer. Front Endocrinol (Lausanne). 2021; 12:686996.

33. Tuttle RM, Fagin J, Minkowitz G, Wong R, Roman B, Patel S, et al. Active surveillance of papillary thyroid cancer: frequency and time course of the six most common tumor volume kinetic patterns. Thyroid. 2022; 32:1337–45.

34. Kim MJ, Moon JH, Lee EK, Song YS, Jung KY, Lee JY, et al. Active surveillance for low-risk thyroid cancers: a review of current practice guidelines. Endocrinol Metab (Seoul). 2024; 39:47–60.

35. Miyauchi A, Kudo T, Ito Y, Oda H, Yamamoto M, Sasai H, et al. Natural history of papillary thyroid microcarcinoma: kinetic analyses on tumor volume during active surveillance and before presentation. Surgery. 2019; 165:25–30.

36. Park S, Chong A, Kang HC, Kim K, Kim SW, Na DG, et al. Korean Thyroid Association guidelines on the management of differentiated thyroid cancers: Part I. Initial management of differentiated thyroid cancers: Chapter 6. Radioactive iodine treatment after thyroidectomy 2024. Int J Thyroidol. 2024; 17:97–110.

37. Dow KH, Ferrell BR, Anello C. Balancing demands of cancer surveillance among survivors of thyroid cancer. Cancer Pract. 1997; 5:289–95.

38. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997; 7:613–9.

39. Ryu CH, Park B, Ryu J, Ryu YM, Jo SA, Lee YJ, et al. Development and evaluation of a Korean version of a Thyroid-Specific Quality-of-Life Questionnaire Scale in thyroid cancer patients. Cancer Res Treat. 2018; 50:405–15.

40. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67:361–70.

41. Sugitani I, Ito Y, Miyauchi A, Imai T, Suzuki S. Active surveillance versus immediate surgery: questionnaire survey on the current treatment strategy for adult patients with low-risk papillary thyroid microcarcinoma in Japan. Thyroid. 2019; 29:1563–71.

42. El Sebaaly R, Mansour M, Labban M, Jaafar RF, Armache A, Mukherji D, et al. Survey on the practice of active surveillance for prostate cancer from the Middle East. Prostate Int. 2020; 8:41–8.

43. Chung SR, Baek JH, Choi YJ, Sung TY, Song DE, Kim TY, et al. Sonographic assessment of the extent of extrathyroidal extension in thyroid cancer. Korean J Radiol. 2020; 21:1187–95.

44. Ito Y, Miyauchi A, Oda H, Kobayashi K, Kihara M, Miya A. Revisiting low-risk thyroid papillary microcarcinomas resected without observation: was immediate surgery necessary? World J Surg. 2016; 40:523–8.

45. Ito Y, Miyauchi A, Kudo T, Higashiyama T, Masuoka H, Kihara M, et al. Kinetic analysis of growth activity in enlarging papillary thyroid microcarcinomas. Thyroid. 2019; 29:1765–73.

46. Liu C, Zhao H, Lu Y, Xia Y, Cao Y, Zhang L, et al. Criteria to evaluate tumor enlargement during the active surveillance of high-risk thyroid nodules: which is better, diameter or volume? World J Surg. 2023; 47:3214–21.